Innoviva, Inc. (NASDAQ:INVA) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System lowered its stake in shares of Innoviva, Inc. (NASDAQ:INVA) by 2.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,946 shares of the biotechnology company’s stock after selling 1,500 shares during the quarter. New York State Teachers Retirement System’s holdings in Innoviva were worth $1,177,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC boosted its position in Innoviva by 18.5% in the 3rd quarter. GAMMA Investing LLC now owns 4,119 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 643 shares in the last quarter. Texas Permanent School Fund Corp boosted its position in Innoviva by 1.4% in the 1st quarter. Texas Permanent School Fund Corp now owns 49,358 shares of the biotechnology company’s stock worth $752,000 after purchasing an additional 662 shares in the last quarter. ProShare Advisors LLC lifted its position in shares of Innoviva by 6.2% during the 1st quarter. ProShare Advisors LLC now owns 16,150 shares of the biotechnology company’s stock valued at $246,000 after buying an additional 942 shares in the last quarter. SummerHaven Investment Management LLC lifted its position in shares of Innoviva by 1.7% during the 2nd quarter. SummerHaven Investment Management LLC now owns 59,853 shares of the biotechnology company’s stock valued at $982,000 after buying an additional 980 shares in the last quarter. Finally, Evergreen Capital Management LLC lifted its position in shares of Innoviva by 10.9% during the 2nd quarter. Evergreen Capital Management LLC now owns 12,321 shares of the biotechnology company’s stock valued at $202,000 after buying an additional 1,209 shares in the last quarter. Institutional investors and hedge funds own 99.12% of the company’s stock.

Innoviva Trading Up 0.9 %

Shares of INVA stock opened at $20.18 on Friday. The stock’s fifty day moving average is $19.61 and its two-hundred day moving average is $17.81. The company has a debt-to-equity ratio of 0.67, a quick ratio of 11.40 and a current ratio of 12.70. The firm has a market capitalization of $1.26 billion, a P/E ratio of 29.25 and a beta of 0.57. Innoviva, Inc. has a fifty-two week low of $13.31 and a fifty-two week high of $20.37.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on INVA. StockNews.com lowered Innoviva from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Innoviva in a research report on Tuesday, July 30th.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.